Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
-95.00%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
RepliCel Life Sciences Inc. (REPCF) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 95.0% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of -0.1%, EPS growth of -262.5%, a dividend yield of 0.0%. What stands out right now is revenue -0.1%, EPS -262.5%, free cash flow +44.2% with operating margin -101.8% and ROIC 49.9%. Valuation is more restrained than many high-expectation growth names at price/sales 3.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines REPCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
REPCF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
REPCF Max Drawdown
-99.50%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for REPCF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$353.7K
+0.0% YoY
FY Net Income
-$1.6M
+61.2% YoY
Free Cash Flow
-$765.2K
+69.6% YoY
Revenue Growth
-0.1%
EPS Growth
-262.5%
Gross Margin
100.0%
Net Margin
-27.5%
Income statement
CAD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 354K | 354K | 354K | 354K | 354K |
| Gross Profit | 354K | 352K | 354K | 354K | 354K |
| Operating Income | -360K | -1M | -1M | -2M | -1M |
| EBITDA | -359K | -1M | -736K | -4M | -2M |
| Net Income | -97K | -312K | -743K | -4M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2K | 59K | 413K | 221K | 34K |
| Total Assets | 147K | 288K | 798K | 592K | 421K |
| Total Liabilities | 5M | 5M | 7M | 7M | 5M |
| Shareholder Equity | -5M | -5M | -6M | -7M | -5M |
| Total Debt | 682K | 873K | 41K | 34K | 76K |
| Net Debt | 680K | 814K | -372K | -187K | 42K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
765K
+69.6% YoY
Capital Expenditures
0
Free Cash Flow
765K
+69.6% YoY
Key ratios
Gross Margin
100.0%
Operating Margin
-101.8%
Net Margin
-27.5%
ROE
1.9%
Debt / Equity
-0.19x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.